Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080431 | 0.86 | MAPT (0.69) | MAPTKMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL8610176 | 0.81 | MAPT (0.62) | MAPTKMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL7611620 | 0.81 | MAPT (0.62) | MAPTKMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL9547929 | 0.80 | KMT2A (0.60) | MAPTKMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL12064923 | 0.79 | MAPT (0.76) | MAPTKMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL8834212 | 0.79 | NR4A2 (0.68) | MAPTKMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL7946523 | 0.78 | MAPT (0.58) | MAPTKMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL8609644 | 0.78 | MAPT (0.59) | MAPTKMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL10598504 | 0.77 | KMT2A (0.55) | MAPTKMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL12065084 | 0.77 | TDP1 (0.67) | MAPTKMT2AMEN1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020204624-A1 | MIRABEGRON PRODRUG COMPOUND, AND PHARMACEUTICAL USE OF SAME FOR TREATING OR IMPROVING OVERACTIVE BLADDER DISEASE | 제이투에이치바이오텍 주식회사 | 2020-10-08 | — | — | WO | disclosed |
| US-20090209585-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090209585-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090209585-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| EP-2039681-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209585-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | SQLE, FDFT1, PTGIS | MAPT 2868/4885KMT2A 4789/4885MEN1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.